807 related articles for article (PubMed ID: 33625511)
1. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
[TBL] [Abstract][Full Text] [Related]
2. An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
Mintz CM; Presnall NJ; Xu KY; Hartz SM; Sahrmann JM; Bierut LJ; Grucza RA
Drug Alcohol Depend; 2021 Sep; 226():108886. PubMed ID: 34245997
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA
J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
[TBL] [Abstract][Full Text] [Related]
5. Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35759785
[No Abstract] [Full Text] [Related]
6. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder.
Mintz CM; Xu KY; Presnall NJ; Hartz SM; Levin FR; Scherrer JF; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211634. PubMed ID: 35544135
[TBL] [Abstract][Full Text] [Related]
8. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
[TBL] [Abstract][Full Text] [Related]
9. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
[TBL] [Abstract][Full Text] [Related]
10. Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder.
Ellis MS; Xu KY; Tardelli VS; Fidalgo TM; Buttram ME; Grucza RA
JAMA Psychiatry; 2023 Dec; 80(12):1269-1276. PubMed ID: 37672238
[TBL] [Abstract][Full Text] [Related]
11. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
[TBL] [Abstract][Full Text] [Related]
12. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
13. Use of naltrexone in treating opioid use disorder in pregnancy.
Towers CV; Katz E; Weitz B; Visconti K
Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
[TBL] [Abstract][Full Text] [Related]
14. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
[TBL] [Abstract][Full Text] [Related]
15. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
16. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
17. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
[TBL] [Abstract][Full Text] [Related]
18. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
Johnson K; Hills H; Ma J; Brown CH; McGovern M
Am J Drug Alcohol Abuse; 2021 Mar; 47(2):220-228. PubMed ID: 33054435
[No Abstract] [Full Text] [Related]
19. Maintenance medication for opiate addiction: the foundation of recovery.
Bart G
J Addict Dis; 2012; 31(3):207-25. PubMed ID: 22873183
[TBL] [Abstract][Full Text] [Related]
20. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
